Development of a Family-Based Treatment for Adolescent Methamphetamine Use (AIMS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The AIMS study compares a methamphetamine-specific treatment intervention to a treatment-as-usual Functional Family Therapy (FFT) approach for adolescents ages 15 to 19. Adolescents are assigned to one of two treatment conditions: (1) 16 weeks of FFT designed to strengthen family relationships and develop skills for helping the adolescent avoid drug use; or (2) 16 weeks of a combination of FFT and a methamphetamine-specific intervention involving group and individual therapy sessions; Families are assessed using questionnaires and interviews, and adolescents participate in neuropsychological testing, before, during, and after treatment to provide information about family functioning, the adolescent's drug use, the adolescent's peers, and other factors that may contribute to treatment success. Adolescents also provide urine specimens for drug screening at assessment visits. Through a partnership with Oregon Health and Science University (OHSU), adolescents will participate in functional magnetic resonance imaging appointments at the hospital to examine regional brain blood flow during tasks designed to measure impulsivity and risk-taking behaviors. As a treatment development grant, study investigators will study adolescents' acceptance of and response to the newly developed methamphetamine-specific treatment approach.
| Condition | Intervention | Phase |
|---|---|---|
|
Behavior and Mental Disorders Methamphetamine Disorders |
Behavioral: Adolescent Methamphetamine Treament (AMT) Behavioral: Functional Family Therapy (FFT) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Development of a Family-Based Treatment for Adolescent Methamphetamine Use |
- Substance Use [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Engagement and retention of adolescent methamphetamine users. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 60 |
| Study Start Date: | September 2007 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Family therapy combined with methamphetamine-specific group treatment.
|
Behavioral: Adolescent Methamphetamine Treament (AMT)
AMT Group Therapy plus Functional Family Therapy (FFT)
|
|
Active Comparator: 2
Family Therapy.
|
Behavioral: Functional Family Therapy (FFT)
FFT
|
Eligibility| Ages Eligible for Study: | 15 Years to 19 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 15 to 19 years of age.
- Have at least one parent or parent figure willing to participate.
- Meet DSM-IV diagnostic criteria for drug-abuse or dependence, including a specific meth use disorder.
- Reports meth use on at least 5 of the previous 90 days.
- Have contact with the parent on at least 40% of the past 90 days.
- With their parent be willing to accept randomization to one of the two treatment interventions.
- Be willing to participate in the imaging task in the fMRI pilot study.
- Have basic English competency.
- Have sufficient residential stability to permit probable contact at follow-up.
Exclusion Criteria:
- Evidence of psychotic or organic state of sufficient severity to interfere with understanding of study instruments and procedures.
- Have a medical or psychological condition that would preclude undergoing the fMRI scan.
- Have a sibling who is participating in the study.
Contacts and Locations| United States, Oregon | |
| Oregon Research Institute Center for Family and Adolescent Research | |
| Portland, Oregon, United States, 97205 | |
| Principal Investigator: | Holly B. Waldron, Ph.D. | Oregon Research Institute |
More Information
Additional Information:
No publications provided
| Responsible Party: | Oregon Research Institute |
| ClinicalTrials.gov Identifier: | NCT00680511 History of Changes |
| Other Study ID Numbers: | DA021695 |
| Study First Received: | May 16, 2008 |
| Last Updated: | May 22, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Oregon Research Institute:
|
methamphetamine abuse |
Additional relevant MeSH terms:
|
Mental Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features Methamphetamine Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Dopamine Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Central Nervous System Stimulants Central Nervous System Agents Therapeutic Uses Adrenergic Agents Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Dopamine Uptake Inhibitors |
ClinicalTrials.gov processed this record on June 18, 2013